Investigation of Mechanisms of Action of FGF1 and FGF21 on the Prevention of Diabetic Retinopathy
ISEF · 2015 Biomedical Engineering
Overview
Type-2 diabetes results when insulin producing beta-cells cannot compensate for rising insulin resistance. Diabetic pathologies may ensue including retinopathies. Current treatments show adverse effects including weight gain, bone loss and risk of CHF. Studies have shown fibroblast growth factor-21 (FGF21), an endocrine FGF, and fibroblast growth factor-1 (FGF1), a non-endocrine FGF, have therapeutic potential by increasing insulin sensitivity through unresolved mechanisms. In the present study, exogenous FGF1 (0-100ng/mL) and FGF21 (0-100ng/mL), were investigated in the murine-photoreceptor cell line, 661W, attempting to elucidate pathways promoting glucose uptake. Proliferation occurred at 10ng/mL FGF1 (p<0.05) and greater than 1ng/mL FGF21 (p<0.01). Insulin receptor expression increased at 100ng/mL FGF1 (p<0.01) and greater than 1ng/mL FGF21 (p<0.05). Glucose uptake increased at 100ng/mL for each FGF (p<0.001). GLUT2 expression increased with FGF1, but decreased at greater than 1ng/mL of FGF21 (p<0.05), suggesting alternative mechanisms. pAKT expression increased at concentrations greater than 1ng/mL in FGF1 treated cells only, while pERK1/2 expression increased at 100ng/mL in FGF21 treated cells only; supporting alternative pathways (p<0.001). LY294002 (PI3K/AKT inhibitor) abolished the FGF1 induced increase in glucose uptake implicating the PI3K/AKT pathway, however the FGF21 increase was unaffected. Inflammatory cytokine, Interleukin-6, decreased across concentrations of FGF21 (p<0.01), yet FGF1 did not affect its production. Green opsin photoreceptor expression was inhibited for each FGF at low doses (p<0.05), with a high dose restorative effect. Both FGF1 and FGF21 appear to have therapeutic potential in the type-2 diabetic retina through alternate mechanisms.
Competition history
- ISEF 2015
Resources
Related projects
ISEF · 2021
Treating Blindness: The Role of Autophagy in Diabetic Retinopathy
ISEF · 2022
Fisetin in an in vitro Model of the Diabetic Eye
ISEF · 2026
Uncovering a New Avenue to Fight Retinal Diseases: Identifying Retinal Ganglion Cells as a Novel Signaling Pathway Through Fixational Eye Movements With Discovery of the ZNF385D Biomarker Group for AKB-9778 Therapeutic Intervention
ISEF · 2026
The Role of VEGF and FGF21 in Restoring the Hypotrophic Response of Endostatin in Neonatal Rat Ventricular Myocytes
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair